

To: 5.1.2e, 5.1.2e, 5.1.2e, 5.1.2e (5.1.2e) | 5.1.2e @minvws.nl; 5.1.2e, 5.1.2e (5.1.2e) | 5.1.2e @minvws.nl; 5.1.2e, 5.1.2e (5.1.2e) | 5.1.2e @minvws.nl; 5.1.2e
 (5.1.2e) | 5.1.2e @minvws.nl; 5.1.2e, 5.1.2e (5.1.2e) | 5.1.2e @minvws.nl
 Cc: 5.1.2e @minbuza.nl; 5.1.2e @minbuza.nl; 5.1.2e, (5.1.2e) | 5.1.2e @minvws.nl
 From: 5.1.2e @ec.europa.eu
 Sent: Fri 11/27/2020 8:51:16 AM
 Subject: RE: C-TAP
 Received: Fri 11/27/2020 8:51:22 AM
[2_EN_ACT_part1_v10\(1\).pdf](#)
[verslag C-TAP meeting .eml](#)

Dag 5.1.2e we spreken elkaar straks om 12.00 uur.

Alvast een paar Brusselse observaties onder (op basis van het deze week door de Commissie gepubliceerde IP Action Plan – **bijlage** – en een mede door SANTE becommentarieerde concept-studie over 'impact licensing').

Zoals je ziet, zijn de Commissie-initiatieven tot nu toe erg gebaseerd op vrijwilligheid van kant IP holder.

We spreken elkaar straks.

5.1.2e

- The Impact Licensing Initiative could enable and incentivise a rapid pooling of critical IP (in times of crisis), **on a voluntary basis**, for diagnostics for protection/treatment/prevention.
- The Medicines Patent Pool (initiative to link pharma companies to access need of ill-resourced countries **on a voluntary basis** – an MoU between the Commission and MPP will be signed in the near future) is seen as a solution for rapid pooling of critical IP for medicinal products/vaccines (also on a voluntary basis).

IP Action Plan (Hoofdstuk 4. EASIER ACCESS TO AND SHARING OF IP-PROTECTED ASSETS)

- "Building on various experiences with pledges and patent pools, the Commission is working on mechanisms that would enable and incentivise the rapid pooling of critical IP in times of crisis, whilst guaranteeing that such voluntary and temporary pooling preserves strong protection of IP. This would offer interested parties the IP tools they need to quickly ramp up the production of IP-protected technologies, including via repurposing manufacturing."
- "The Commission calls on the Member States to ensure that the tools they have are as effective as possible, for instance, by putting in place fast-track procedures for issuing compulsory licenses in emergency situations."

Study impact licensing (is door DG GROW uitgevoerd – nog niet openbaar)

- The study presents an "impact licensing model" that resolves technology access disruption during an international (health) crisis (one of the four 'types' of products are medicines/vaccines).
 - "Impact Licensing Initiative" ("ILI") exists since 2019 as a Belgian-based non-profit organisation (<http://www.impactlicensing.org/>)
- Strong link to attaining the UN sustainable-development goals ("SDGs")
- ILI proposes a collaborative and voluntary platform for technology owners, manufacturers and user organizations to guarantee access to essential technologies during such crisis where the interest of every actor is taken in consideration. The model offers an alternative for compulsory licensing mechanisms, by allowing on one hand to technology owners the continued control over their rights, and to ensure on the other hand to society continued and affordable technology access through local manufacturing.
- ILI can take a role adjacent to that of the MPP to help it tackling the COVID 19 crisis. ILI studies impact licensing for technologies to safely and efficiently distributing a vaccine (cold chain logistics) and for diagnostics for protection/treatment/prevention. For instance, ILI has access to a promising cold chain technology for transportation and storage of COVID 19 vaccines

Kanttekeningen

- ILI is a voluntary platform, so no obligation for (IP) technology owners to participate
- Should not be an alternative to possibility of compulsory licensing (but this seems not to be the case – see

IP Action Plan)

- Vaccines/medicinal products are seen as a 'distinct' category, and not directly suitable for impact licensing
- Instead, Medicines Patent Pool (initiative to link pharma companies to access need of ill-resourced countries on voluntary basis) is seen as solution for medicinal products/vaccines

-----Original Appointment-----

From: [REDACTED], [REDACTED], [REDACTED], [REDACTED] ([REDACTED]) <[REDACTED]@minvws.nl>

Sent: Friday, November 20, 2020 12:46 PM

To: [REDACTED], [REDACTED], [REDACTED], [REDACTED] ([REDACTED]); [REDACTED], [REDACTED] (SANTE); [REDACTED], [REDACTED], [REDACTED]; [REDACTED], [REDACTED] ([REDACTED]); [REDACTED], [REDACTED], [REDACTED]

Cc: [REDACTED], [REDACTED]

Subject: C-TAP

When: Friday, 27 November 2020 12:00-13:00 (UTC+01:00) Amsterdam, Berlin, Bern, Rome, Stockholm, Vienna.

Where: webex

VWS IZ en GMT, BRU en GEV bijpraten over C-TAP initiatief

-- De volgende tekst niet verwijderen of wijzigen. --

Er is een Webex-vergadering toegevoegd. De vergaderingsinformatie wordt in dit gedeelte weergegeven nadat u de uitnodiging hebt opgeslagen of verzonden.